AU646522B2 - Diagnosis and treatment of multiple sclerosis - Google Patents
Diagnosis and treatment of multiple sclerosisInfo
- Publication number
- AU646522B2 AU646522B2 AU89555/91A AU8955591A AU646522B2 AU 646522 B2 AU646522 B2 AU 646522B2 AU 89555/91 A AU89555/91 A AU 89555/91A AU 8955591 A AU8955591 A AU 8955591A AU 646522 B2 AU646522 B2 AU 646522B2
- Authority
- AU
- Australia
- Prior art keywords
- msv
- antibody
- antigen
- antigenic fragment
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 201000006417 multiple sclerosis Diseases 0.000 title claims description 88
- 238000003745 diagnosis Methods 0.000 title description 9
- 241000700605 Viruses Species 0.000 claims description 66
- 210000004027 cell Anatomy 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 44
- 239000000427 antigen Substances 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 230000000890 antigenic effect Effects 0.000 claims description 28
- 210000005013 brain tissue Anatomy 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 27
- 210000004248 oligodendroglia Anatomy 0.000 claims description 24
- 210000001519 tissue Anatomy 0.000 claims description 17
- 210000004556 brain Anatomy 0.000 claims description 16
- 229960005486 vaccine Drugs 0.000 claims description 15
- 241000282414 Homo sapiens Species 0.000 claims description 13
- 241000282324 Felis Species 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 10
- 241000282326 Felis catus Species 0.000 claims description 9
- 230000002238 attenuated effect Effects 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000002163 immunogen Effects 0.000 claims description 7
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- 238000012760 immunocytochemical staining Methods 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 5
- 210000004408 hybridoma Anatomy 0.000 claims description 5
- 102000018358 immunoglobulin Human genes 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 235000011330 Armoracia rusticana Nutrition 0.000 claims description 4
- 240000003291 Armoracia rusticana Species 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 210000004754 hybrid cell Anatomy 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 2
- 108010058846 Ovalbumin Proteins 0.000 claims description 2
- 229940037003 alum Drugs 0.000 claims description 2
- 229940098773 bovine serum albumin Drugs 0.000 claims description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims description 2
- 229940092253 ovalbumin Drugs 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 6
- 229940127121 immunoconjugate Drugs 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 description 17
- 241000712083 Canine morbillivirus Species 0.000 description 14
- 239000002245 particle Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 201000005505 Measles Diseases 0.000 description 8
- 238000001042 affinity chromatography Methods 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 241000712079 Measles morbillivirus Species 0.000 description 7
- 210000001130 astrocyte Anatomy 0.000 description 7
- 210000003000 inclusion body Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000003967 CLP Anatomy 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 6
- 101150038575 clpS gene Proteins 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- 102000012438 2',3'-Cyclic-Nucleotide Phosphodiesterases Human genes 0.000 description 5
- 108010022794 2',3'-Cyclic-Nucleotide Phosphodiesterases Proteins 0.000 description 5
- 208000000655 Distemper Diseases 0.000 description 5
- 208000014058 canine distemper Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001493 electron microscopy Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 230000003210 demyelinating effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- JVIPLYCGEZUBIO-UHFFFAOYSA-N 2-(4-fluorophenyl)-1,3-dioxoisoindole-5-carboxylic acid Chemical compound O=C1C2=CC(C(=O)O)=CC=C2C(=O)N1C1=CC=C(F)C=C1 JVIPLYCGEZUBIO-UHFFFAOYSA-N 0.000 description 2
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229920001425 Diethylaminoethyl cellulose Polymers 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 101001013648 Homo sapiens Methionine synthase Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000712045 Morbillivirus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003140 astrocytic effect Effects 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- 102000000563 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase Human genes 0.000 description 1
- 108010041801 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase Proteins 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- SNMOMUYLFLGQQS-UHFFFAOYSA-N 8-bromooct-1-ene Chemical compound BrCCCCCCC=C SNMOMUYLFLGQQS-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241000714201 Feline calicivirus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000007634 Peste-des-Petits-Ruminants Diseases 0.000 description 1
- 241000711899 Phocine morbillivirus Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 241000711897 Rinderpest morbillivirus Species 0.000 description 1
- 235000005121 Sorbus torminalis Nutrition 0.000 description 1
- 244000152100 Sorbus torminalis Species 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005088 multinucleated cell Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000010984 neurological examination Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical compound [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU89555/91A AU646522B2 (en) | 1990-11-14 | 1991-11-14 | Diagnosis and treatment of multiple sclerosis |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPK335290 | 1990-11-14 | ||
| AUPK3352 | 1990-11-14 | ||
| AU89555/91A AU646522B2 (en) | 1990-11-14 | 1991-11-14 | Diagnosis and treatment of multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU8955591A AU8955591A (en) | 1992-06-11 |
| AU646522B2 true AU646522B2 (en) | 1994-02-24 |
Family
ID=3775068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU89555/91A Ceased AU646522B2 (en) | 1990-11-14 | 1991-11-14 | Diagnosis and treatment of multiple sclerosis |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0557388A4 (de) |
| JP (1) | JP3266612B2 (de) |
| AU (1) | AU646522B2 (de) |
| CA (1) | CA2095539A1 (de) |
| WO (1) | WO1992008785A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK173091D0 (da) * | 1991-10-11 | 1991-10-11 | Schleroseforeningen The Danish | Biologisk materiale |
| GB9310657D0 (en) * | 1993-05-24 | 1993-07-07 | Univ London | Retrovirus |
| WO1999053103A1 (en) * | 1998-04-08 | 1999-10-21 | Ms Research A/S | Diagnosis of multiple sclerosis and other demyelinating diseases |
| BR0112969A (pt) | 2000-08-04 | 2004-06-22 | Dmi Biosciences Inc | Método de utilização de dicetopiperazinas e composições contendo-as |
| EP1571970B1 (de) | 2002-10-02 | 2011-08-17 | DMI Biosciences, Inc. | Diagnose und überwachung von krankheiten |
| US7732403B2 (en) | 2003-05-15 | 2010-06-08 | Dmi Biosciences, Inc. | Treatment of T-cell mediated diseases |
| US8217047B2 (en) | 2008-05-27 | 2012-07-10 | Dmi Acquisition Corp. | Therapeutic methods and compounds |
| CA2810844C (en) | 2010-09-07 | 2017-03-21 | Dmi Acquisition Corp. | Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions |
| PL2766029T3 (pl) | 2011-10-10 | 2020-08-24 | Ampio Pharmaceuticals, Inc. | Leczenie choroby zwyrodnieniowej stawów |
| WO2013055749A1 (en) | 2011-10-10 | 2013-04-18 | Ampio Pharmaceuticals, Inc. | Implantable medical devices with increased immune tolerance, and methods for making and implanting |
| JP6231484B2 (ja) | 2011-10-28 | 2017-11-15 | アンピオ ファーマシューティカルズ，インコーポレイテッド | 鼻炎の処置 |
| CN105101965B (zh) | 2013-03-15 | 2021-03-09 | 安皮奥制药股份有限公司 | 用于干细胞活动化、归巢、扩增和分化的组合物及其使用方法 |
| RU2736513C2 (ru) | 2014-08-18 | 2020-11-17 | Ампио Фармасьютикалз, Инк. | Лечение патологических состояний суставов |
| EP3310375A4 (de) | 2015-06-22 | 2019-02-20 | Ampio Pharmaceuticals, Inc. | Verwendung von niedermolekularen fraktionen von humanem serumalbumin bei der behandlung von erkrankungen |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ218050A (en) * | 1985-11-13 | 1989-05-29 | Wistar Inst | Test for the presence of htlv-1v |
| EP0326395A2 (de) * | 1988-01-29 | 1989-08-02 | City Of Hope | Verfahren zum Nachweis und zur Identifizierung von bestimmten viralen Sequenzien |
-
1991
- 1991-11-14 JP JP50018192A patent/JP3266612B2/ja not_active Expired - Fee Related
- 1991-11-14 EP EP19910920470 patent/EP0557388A4/en not_active Withdrawn
- 1991-11-14 CA CA002095539A patent/CA2095539A1/en not_active Abandoned
- 1991-11-14 WO PCT/AU1991/000519 patent/WO1992008785A1/en not_active Application Discontinuation
- 1991-11-14 AU AU89555/91A patent/AU646522B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO1992008785A1 (en) | 1992-05-29 |
| AU8955591A (en) | 1992-06-11 |
| CA2095539A1 (en) | 1992-05-15 |
| JPH06502764A (ja) | 1994-03-31 |
| EP0557388A4 (en) | 1994-07-06 |
| JP3266612B2 (ja) | 2002-03-18 |
| EP0557388A1 (de) | 1993-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU646522B2 (en) | Diagnosis and treatment of multiple sclerosis | |
| Ludwig et al. | Biology and neurobiology of Borna disease viruses (BDV), defined by antibodies, neutralizability and their pathogenic potential | |
| US4790987A (en) | Viral glycoprotein subunit vaccine | |
| Pugh et al. | Susceptibility to duck hepatitis B virus infection is associated with the presence of cell surface receptor sites that efficiently bind viral particles | |
| US4517304A (en) | Production of viral antigens | |
| EP0755684B1 (de) | Impfstoffkonjugat | |
| Weller et al. | Coxsackievirus-B3-induced myocarditis: virus receptor antibodies modulate myocarditis. | |
| AU3231695A (en) | Antigenic peptides derived from the g protein of rsv for type- and subtype-specific diagnosis of respiratory syncytial virus (rsv) infection | |
| CN115947835B (zh) | 靶向乙型流感病毒核蛋白的抗体及其应用 | |
| WO2010148117A1 (en) | Therapeutic and diagnostic affinity purified specific polyclonal antibodies | |
| WO1996041874A1 (en) | Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection | |
| KR20020020260A (ko) | 서코바이러스를 생장시키거나 생물학적 물질로부터제거하는 방법 | |
| US5397568A (en) | Method of treating infectious bursal disease virus infections | |
| WO2007126655A1 (en) | Eggs having increased antibody titer and methods for making same | |
| CN115838421A (zh) | 靶向乙型流感病毒核蛋白的抗体及其应用 | |
| Kristensson et al. | Sendai virus infection in the brains of mice: distribution of viral antigens studied with monoclonal antibodies | |
| JP2681063B2 (ja) | 腎症候性出血熱ウイルス抗原の製造方法、及び該抗原を含有するワクチン並びに腎症候性出血熱診断剤 | |
| Russell et al. | A rapid enzyme-linked semi-microwell assay for the enumeration of antibody-forming cells to viral and bacterial antigens in domestic animals | |
| JP3527238B2 (ja) | 新規なａ型肝炎ウイルス株、新規なａ型肝炎ウイルス株の分離方法及びａ型肝炎ワクチン | |
| CN115724959B (zh) | 靶向甲型流感病毒核蛋白的抗体及其应用 | |
| Choi et al. | Characterization of Antigenic Sites on the Rinderpest Virus N Protein Uusing Monoclonal Antibodies | |
| Wang et al. | Serum TABM produced during anterior chamber-associated immune deviation passively transfers suppression of delayed-type hypersensitivity to primed mice. | |
| CN115819566B (zh) | 靶向甲型流感病毒核蛋白的抗体及其应用 | |
| Örvell | IDENTIFICATION OF PARAMYXOVIRUS‐SPECIFIC HAEMOLYSIS‐INHIBITING ANTIBODIES SEPARATE FROM HAEMAGGLUTINATING‐INHIBITING AND NEURAMINIDASE‐INHIBITING ANTIBODIES: 2. NDV and Mumps Virus Haemolysis‐inhibiting Antibodies | |
| Ling | Polypeptides of murine and avian pneumoviruses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |